Bristol-Myers announces three-year follow-up results from CheckMate-816 study

Bristol Myers Squibb announced three-year follow-up results from the Phase 3 CheckMate -816 trial, demonstrating sustained clinical benefits with three cycles of Opdivo in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non-small cell lung cancer, or NSCLC. "With median follow up of 41.4 months, Opdivo with chemotherapy reduced the risk of disease recurrence, progression or death by 32%, demonstrating a landmark three-year event-free survival rate of 57% with Opdivo with chemotherapy compared to 43% with chemotherapy alone. Additionally, time to distant metastasis or death, defined as the time between the date of randomization and the first date of distant metastasis or the date of death in the absence of distant metastasis, continued to favor Opdivo with chemotherapy compared to chemotherapy alone, with three-year landmark TTDM rates of 71% vs. 50%, respectively. While overall survival, or OS, remained immature at this analysis, there was a continued encouraging trend in OS favoring neoadjuvant Opdivo with chemotherapy over chemotherapy alone," the company stated.